Get the Stockscreener App
10.58
1.49%
-0.16
After Hours:
10.58
Anika Therapeutics Inc stock is traded at $10.58, with a volume of 60,670.
It is down -1.49% in the last 24 hours and down -5.11% over the past month.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
See More
Previous Close:
$10.74
Open:
$10.84
24h Volume:
60,670
Relative Volume:
0.90
Market Cap:
$165.64M
Revenue:
$166.88M
Net Income/Loss:
$-74.18M
P/E Ratio:
-2.0868
EPS:
-5.07
Net Cash Flow:
$1.14M
1W Performance:
-3.11%
1M Performance:
-5.11%
6M Performance:
-35.72%
1Y Performance:
-58.23%
1-Day Range:
$10.49
$10.88
1-Week Range:
$10.49
$11.43
52-Week Range:
$10.47
$29.11
Anika Therapeutics Inc Stock (ANIK) Company Profile
Name
Anika Therapeutics Inc
Sector
Phone
(781) 457-9000
Address
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
10.58 | 165.64M | 166.88M | -74.18M | 1.14M | -5.07 |
|
RGC
Regencell Bioscience Holdings Ltd
|
17.04 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
155.95 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.37 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.46 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.76 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | B. Riley Securities | Buy |
| Nov-01-24 | Reiterated | Barrington Research | Outperform |
| Aug-14-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Mar-07-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-09-22 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-14-22 | Resumed | Stephens | Equal-Weight |
| Mar-09-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-09-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-16-21 | Initiated | Stephens | Overweight |
| Jul-16-21 | Initiated | UBS | Neutral |
| Dec-16-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-21-20 | Upgrade | Sidoti | Neutral → Buy |
| Jan-10-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Nov-05-19 | Initiated | BWS Financial | Sell |
| Sep-24-19 | Reiterated | Barrington Research | Outperform |
| Sep-23-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Strong Buy |
| Feb-22-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Feb-22-19 | Downgrade | Sidoti | Buy → Neutral |
| Jul-27-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jun-20-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-20-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| May-04-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-23-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-24-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Oct-27-17 | Reiterated | Barrington Research | Outperform |
| May-09-16 | Upgrade | Singular Research | BUY - Long-Term → Buy |
| Apr-27-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-26-16 | Reiterated | Barrington Research | Outperform |
View All
Anika Therapeutics Inc Stock (ANIK) Latest News
Comparing Vivos (OTCMKTS:RDGL) & Anika Therapeutics (NASDAQ:ANIK) - Defense World
Two Sigma Investments LP Cuts Stock Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Bank of America Corp DE Boosts Stake in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Millennium Management LLC Sells 14,006 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Squarepoint Ops LLC Invests $212,000 in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Acquired by Wellington Management Group LLP - Defense World
Mackenzie Financial Corp Invests $231,000 in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Public Employees Retirement System of Ohio Invests $137,000 in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ANIK Stock News - GuruFocus
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Latest: Orthopedics Leader Anika Therapeutics Issues New Employee Stock Options Worth $28,625 - Stock Titan
Kalkine Biggest NASDAQ Companies Including Anika Therapeutics in Biotechnology Sector - Kalkine Media
Two Sigma Advisers LP Sells 12,800 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Ameriprise Financial Inc. Boosts Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Long Term Trading Analysis for (ANIK) - news.stocktradersdaily.com
Jane Street Group LLC Acquires 3,065 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
BNP Paribas Financial Markets Increases Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Deutsche Bank AG Lowers Stock Position in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Orthopedic Regenerative Medicine Market Is Booming Worldwide | - openPR.com
Anika Therapeutics focuses on Hyalofast and Cingal advancements for 2025 growth - MSN
Anika Therapeutics (ANIK) Sees Target Price Adjustment Amid Futu - GuruFocus
Tower Research Capital LLC TRC Acquires 2,326 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Anika Therapeutics (NASDAQ:ANIK) Downgraded by StockNews.com to “Hold” - Defense World
Anika Therapeutics (ANIK) Stock Maintains "Outperform" Rating De - GuruFocus
Viscosupplementation Market: Executive Briefing & Strategic - openPR.com
Company News for May 12, 2025 - Zacks Investment Research
Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates - MSN
Wells Fargo & Company MN Boosts Stock Position in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Investor Network: Anika Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2025 Earnings Call Transcript - Insider Monkey
Anika Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price - simplywall.st
Anika Therapeutics (ANIK) Faces OEM Challenges Amid Commercial G - GuruFocus
Dimensional Fund Advisors LP Sells 50,011 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Anika: Q1 Earnings Snapshot - News-Times
Anika Reports First Quarter 2025 Financial Results - GlobeNewswire
Anika Therapeutics Inc (ANIK) Q1 2025 Earnings Call Highlights: Strategic Growth Amidst Revenue ... - Yahoo Finance
Anika Therapeutics Inc (ANIK) Q1 2025 Earnings Call Highlights: Strategic Growth Amidst Revenue Challenges - GuruFocus
Earnings call transcript: Anika Therapeutics Q1 2025 misses forecasts, shares fall - Investing.com Nigeria
Anika Therapeutics Reports Mixed Q1 2025 Results - TipRanks
Anika Therapeutics’ Mixed Earnings Call Reveals Challenges and Growth - TipRanks
Anika Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$0.28 M - GuruFocus
Anika Therapeutics (ANIK) Faces OEM Challenges Amid Commercial Growth - GuruFocus
Anika Therapeutics (ANIK) Reports Revenue Miss, Highlights Strat - GuruFocus
Anika Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$0.28 Misses Estimate, Revenue of $26.2M Below Expectations - GuruFocus
Anika Therapeutics Posts Wider Loss From Cont. Ops. In Q1 - Nasdaq
Anika (ANIK) Revises 2025 Revenue and Adjusted EBITDA Outlook | ANIK Stock News - GuruFocus
Anika Therapeutics Reports 18% Growth in Commercial Channel Revenue for Q1 2025 Despite Overall Revenue Decline - Nasdaq
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2024 Earnings Call Transcript - MSN
Barclays PLC Buys 2,093 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Earnings To Watch: Anika Therapeutics Inc (ANIK) Reports Q1 2025 Result - GuruFocus
Anika Therapeutics Inc Stock (ANIK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anika Therapeutics Inc Stock (ANIK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
| Nunes Anne | SVP, Chief Operations Officer |
Oct 01 '24 |
Option Exercise |
0.00 |
2,491 |
0 |
14,211 |
0.07%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):